PMID- 19836626
OWN - NLM
STAT- MEDLINE
DCOM- 20100201
LR  - 20220318
IS  - 1872-6976 (Electronic)
IS  - 0167-4943 (Linking)
VI  - 49 Suppl 1
DP  - 2009
TI  - Impact of therapy with alpha-lipoic acid (ALA) on the oxidative stress in the 
      controlled NIDDM: a possible preventive way against the organ dysfunction?
PG  - 129-33
LID - 10.1016/j.archger.2009.09.022 [doi]
AB  - There is a growing evidence that excess generation of highly reactive free 
      radicals, largely due to hyperglycemia, causes oxidative stress, which further 
      exacerbates the development and progression of diabetes and its complications. 
      The purpose of this study was to evaluate the impact of ALA on lipid profile, 
      oxidative pattern and inflammation in patients with controlled non-insulin 
      dependent diabetes mellitus (NIDDM). ALA, 400mg/day was investigated in NIDDM 
      patients over a period of 4 weeks using a randomized, placebo-(PLA)-controlled 
      study with two parallel groups. The marker of oxidative stress was the 
      concentration of reactive oxygen metabolites, evaluated using a commercially 
      available test, called d-ROMs test, and the biological antioxidant potential 
      (BAP); besides, the lipid profile (total cholesterol=TC, high-density 
      lipoprotein-cholesterol = HDL-C; low-density lipoprotein-cholesterol=LDL-C, and 
      triglycerides=TG) and the C-reactive protein (CRP), marker of inflammation were 
      measured at the beginning and at the end of the treatment. A total of 14 patients 
      were randomly assigned to the two groups. ALA was safe and well tolerated in the 
      only oral daily administration. The d-ROMs test (p=0.03) and HDL-C (p=0.04) 
      showed a significant difference between the two groups. BAP (p=0.06) tended to be 
      higher in the treated patients, while LDL-C (p=0.07) presented a moderate 
      decline. There were no significant differences in TC (p=0.65), TG (p=0.78) and 
      CRP (p=0.96) between the ALA and PLA groups. ALA therapy appears to reduce 
      significantly d-ROMs and to improve HDL-C value, especially in men with metabolic 
      syndrome treated with oral hypoglycemic drugs. These findings will be useful in 
      patient selection in future clinical trials with ALA in long term studies.
FAU - Gianturco, V
AU  - Gianturco V
AD  - Dipartimento di Scienze dell'Invecchiamento, Sapienza Universita di Roma, Umberto 
      I Policlinico di Roma, Roma, Italy.
FAU - Bellomo, A
AU  - Bellomo A
FAU - D'Ottavio, E
AU  - D'Ottavio E
FAU - Formosa, V
AU  - Formosa V
FAU - Iori, A
AU  - Iori A
FAU - Mancinella, M
AU  - Mancinella M
FAU - Troisi, G
AU  - Troisi G
FAU - Marigliano, V
AU  - Marigliano V
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Netherlands
TA  - Arch Gerontol Geriatr
JT  - Archives of gerontology and geriatrics
JID - 8214379
RN  - 0 (Antioxidants)
RN  - 0 (Cholesterol, HDL)
RN  - 0 (Cholesterol, LDL)
RN  - 0 (Reactive Oxygen Species)
RN  - 73Y7P0K73Y (Thioctic Acid)
RN  - 9007-41-4 (C-Reactive Protein)
SB  - IM
MH  - Administration, Oral
MH  - Antioxidants/administration & dosage/*therapeutic use
MH  - C-Reactive Protein/metabolism
MH  - Cholesterol, HDL/blood
MH  - Cholesterol, LDL/blood
MH  - Diabetes Complications/blood/*drug therapy
MH  - Double-Blind Method
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Oxidative Stress/*drug effects
MH  - Reactive Oxygen Species/blood
MH  - Thioctic Acid/administration & dosage/*therapeutic use
MH  - Treatment Outcome
EDAT- 2009/10/27 06:00
MHDA- 2010/02/02 06:00
CRDT- 2009/10/20 06:00
PHST- 2009/10/20 06:00 [entrez]
PHST- 2009/10/27 06:00 [pubmed]
PHST- 2010/02/02 06:00 [medline]
AID - S0167-4943(09)00222-2 [pii]
AID - 10.1016/j.archger.2009.09.022 [doi]
PST - ppublish
SO  - Arch Gerontol Geriatr. 2009;49 Suppl 1:129-33. doi: 
      10.1016/j.archger.2009.09.022.